Autor(es): Conceição I,Carvalho M,Alves M,Parreira E,Martins A,Ferro J,Sales-Luis M L

Resumo: We carried out a case a case-control study to analyze the relationship between parenteral gangliosides administration and the Guillain-Barré syndrome. We retrieved 64 patients with the diagnosis of Guillain-Barré syndrome, and 148 controls. In cases and controls the proportion and 95% confidence intervals (CI) of subject receiving gangliosides, was calculated. The number of patients with the Guillain-Barré syndrome who needed ventilation or died was also calculated. Four of 36 patients (95% CI = 81-0.6), over 40 years, received gangliosides prior to Guillain-Barré syndrome. One of these patients was ventilated (95% CI = 25-2) and died. None of the controls less than 40 years old took gangliosides, while from the 108 over 40 (95% CI = 15-4) 9 received gangliosides. None developed signs suggesting Guillain-Barré syndrome. Although gangliosides were more often used in Guillain-Barré syndrome (OR = 1.75), the difference was not significant (95% CI = 4.82-0.69). The present work proves that in spite of the association of Guillain-Barré syndrome, with gangliosides intake, there is no statistical difference between this group of patients and control population.

Palavras-Chave: Nervios periféricos ; Unión neuromuscular y músculo

Imprenta: Revista de Neurologia, v. 28, n. 11, p. 1033-1035, 1999

Descritores: Guillain-Barre Syndrome - Public health

Data de publicação: 1999

Indicadores

ACESSO